

DRUG PRIOR AUTHORIZATION COMMITTEE
December 20, 2018

AGENDA

Missouri Coalition for Community Behavioral Healthcare
Lower Level CEO Room, 221 Metro Drive
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Mitch Ruth
10:25 - 10:35	DUR Update	Mark Roaseau

Old Business

10:35 – 10:45	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Mark Roaseau
---------------	--	--------------

New Business

10:45 – 11:30	B. Proposed Actions - New Drug/Product Review (See website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Productsiv. Prior Authorization<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Mark Roaseau
---------------	--	--------------

11:30 – 11:45	C. <u>Clinical Edits</u>	
---------------	---------------------------------	--

I.Orlissa Clinical Edit

- Discussion
- Public Hearing
- Decision

II.Galafold Clinical Edit

- Discussion
- Public Hearing
- Decision

III.Onpattro Clinical Edit

- Discussion
- Public Hearing
- Decision

D. Preferred Drug List (PDL)

- I. **Alzheimer's Agents**
 - Discussion
 - Public Hearing
 - Decision
- II. **Antiemetic 5-HT3 and Other Agents**
 - Discussion
 - Public Hearing
 - Decision
- III. **Antiemetic, Substance P/Neurokinin1 (NK1) Receptor Agonist Agents**
 - Discussion
 - Public Hearing
 - Decision
- IV. **Antiemetic, THC Derivative Agents**
 - Discussion
 - Public Hearing
 - Decision
- V. **Anti-Migraine, Serotonin (5-HT1) Receptor Agents**
 - Discussion
 - Public Hearing
 - Decision
- VI. **Anti-Parkinsonism MAOI-B Agents (New)**
 - Discussion
 - Public Hearing
 - Decision
- VII. **Antipsychotics – 2nd Generation (Atypical) Reference Product List (New)**
 - Discussion
 - Public Hearing
 - Decision
- VIII. **Cox-II Inhibitor Agents**
 - Discussion
 - Public Hearing
 - Decision
- IX. **Electrolyte Depleters, Potassium Lowering Agents (New)**
 - Discussion
 - Public Hearing
 - Decision
- X. **Fibromyalgia Agents**
 - Discussion
 - Public Hearing
 - Decision

- XI. Hereditary Angioedema Treating Agents (NEW)**
 - Discussion
 - Public Hearing
 - Decision
- XII. IBS, Anti-Diarrheal Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIII. IBS-C/CIC Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIV. Neuropathic Pain Agents**
 - Discussion
 - Public Hearing
 - Decision
- XV. Non-Ergot Dopamine Receptor Agonist Agents**
 - Discussion
 - Public Hearing
 - Decision
- XVI. NSAID Agents**
 - Discussion
 - Public Hearing
 - Decision
- XVII. Opioid Dependence Agents**
 - Discussion
 - Public Hearing
 - Decision
- XVIII. Opioid Emergency Reversal Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIX. Opioid Induced Constipation Agents**
 - Discussion
 - Public Hearing
 - Decision
- XX. Opioids, Long-Acting Agents**
 - Discussion
 - Public Hearing
 - Decision
- XXI. Sedative-Hypnotic Agents**
 - Discussion
 - Public Hearing
 - Decision

XXII. Skeletal Muscle Relaxant Agents

- Discussion
- Public Hearing
- Decision

XXIII. Thrombocytopenia Treating Agents (New)

- Discussion
- Public Hearing
- Decision

XXIV. Tramadol-Like Agents

- Discussion
- Public Hearing
- Decision

F. Preferred Drug List Classes for March/April

- i.Process Discussion
- ii.Therapeutic classes/to be announced at meeting

1:00-1:30

LUNCH

1:15-1:30

**Program Utilization Information
Conduent Update**

Mark Roaseau/
Josh Moore

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: Thursday, March 21, 2019

**Missouri Coalition for Community Behavioral Healthcare
221 Metro Dr. Lower Level, CEO Room
Jefferson City, MO**